Tag: Vaccine Production

The production of a quadrivalent influenza vaccine was launched in Podolsk

The vaccine was registered in 2018 and became Russia's first quadrivalent influenza vaccine - it protects against two influenza A virus infection (H1N1 and H3N2) and two influenza B virus infection.

The European Investment Bank provided a €30 million loan for Bavarian Nordic

Bavarian Nordic announced the securing of a loan facility of €30 million from the European Investment Bank (EIB), the long-term lending institution of the European Union owned by its Member States.

Chinese drug regulator launches investigation of all vaccine manufacturers

The National Drug Administration of China (CNDA) launched a thorough investigation into all vaccine producers across the country. Chinese drug producer had violated standards in making of DPT vaccine.

The Russian government will fund the reconstruction of Microgen

The Russian government decided to provide a subsidy from the federal budget to NPO Microgen for the reconstruction and technical re-equipment of its production facilities for influenza vaccines in 2018-2021.

Kirov pharma cluster participants explored biotech development in France

The delegation of the government of the Kirov region visited the Lyonbiopôle in France, which is largest pharmaceutical cluster in the world.

FORT increases its sales of influenza vaccine

In 2018, FORT, a biopharmaceutical company which is part of Marathon Group and Nacimbio (Rostec Corporation), doubled its yoy sales of Ultrex, an influenza vaccine.

Nacimbio supplied more than 1 million doses of TBE vaccine

In January - May 2018, Nacimbio, a pharmaceutical holding company of Rostec Corporation, has supplied to all regions of Russia more than 1 million doses of vaccines for prevention of tick-borne encephalitis (TBE).

Russia will have its first quadrivalent influenza vaccine

According to the experts, this vaccine has not only the most effective and safe profile possible today, but also provides undeniable pharmacoeconomic advantages.

Today’s realities in the development of local and contract manufacturing

The representatives of pharmaceutical companies met at the forum of the Adam Smith Institute where they shared their views on the development of local and contract manufacturing.

Microgen increased its medicines output by 16%

NPO Microgen, a subsidiary of Nacimbio (part of Rostec Corporation), published its results for 2017. The company's revenue reached 7.7 billion rubles.

Nacimbio was designated as vaccines supplier for National Vaccination Schedule

Nacimbio JSC, a pharmaceutical holding company of Rostec Corporation, received the status of sole supplier of immunobiological medicines used for vaccinations under the National Vaccination Schedule.

Sanofi will pump €350 million into construction of its new Canadian facility

Sanofi, a leading global pharmaceutical company, is investing €350 million for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.

A memorandum signed to promote Russian products onto the Chilean market

The representatives of the Public Health Institute of Chile visited a vaccine production facility of St. Petersburg Institute of Vaccines and Serums in order to continue and expand cooperation between Russia and Chile.

3P Biopharmaceuticals signed a contract manufacturing agreement with Intervacc

3P Biopharmaceuticals, a Spanish biotechnology company, and the Swedish company Intervacc completed negotiations and signed the agreement for contract manufacturing of Strangvac®.

In 2017 Nanolek demonstrates the first results of its active market development

In 2017, the revenue of Nanolek LLC reached 2.6 billion rubles, which is a 3-fold increase compared to 2016. The output of medicinal products at the Nanolek plant in the Kirov region amounted to 8.1 million packages.

Vnesheconombank restructures the debt of Ryazan-based FORT

Vnesheconombank allowed FORT, a pharmaceutical manufacturer based in Ryazan, to continue using its credit facility on the terms favorable for the company